TP53 and acute myeloid leukemia: Interestingly, STAG2 and RAD21 mutations shared a near-mutational exclusivity with TP53 mutations (OR = 0.04–0.06, FDR < 0.001), which was evident for MDS and AML cases (ORSTAG2-MDS = 0.07, ORSTAG2-AML = 0.05, ORRAD21-MDS = 0, ORRAD21-AML = 0.08).